X0609 4 2026-08-26 0 0000315545 PROVECTUS BIOPHARMACEUTICALS, INC. PVCT 0001689739 Pershing Edward false 800 S. GAY STREET, SUITE 1610 KNOXVILLE TN 37929 1 1 1 0 CEO 0 8% Unsecured Convertible Promissory Note 2.862 2026-08-26 4 M 0 30000 0 D 2025-08-26 2026-08-26 Series D-1 Convertible Preferred Stock 11328 840000 D Series D-1 Convertible Preferred Stock 2026-08-26 4 M 0 11328 0 A 2026-08-26 Common Stock 113280 2924949 D Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on December 31, 2028, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock. The Reporting Person could have voluntarily elected to convert the outstanding principal and interest of the 8% unsecured convertible promissory note (the "2025 Note") at any time while the 2025 Note was outstanding into shares of Series D-1 Convertible Preferred Stock at a price per share equal to $2.862. The outstanding principal and interest of the 2025 Note automatically converted into shares of Series D-1 Preferred Stock at a price per share equal to $2.862 on the date which is twelve months after the issue date of the 2025 Note. The 2025 Note was issued pursuant to the Issuer's 2025 Financing. On August 26, 2026, the 2025 Note converted into 11,328 shares of Series D-1 Preferred Stock. The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person. The amount reported reflects an adjustment to correct a typographical error in a previously filed Form 4. This adjustment does not reflect a transaction by the Reporting Person. /s/ Ed Pershing 2026-08-26